Invasive pneumococcal disease in Australia, 2005
DOI:
https://doi.org/10.33321/cdi.2007.31.4Keywords:
disease surveillance, pneumococcal disease, Streptococcus pneumoniaeAbstract
Enhanced surveillance for invasive pneumococcal disease (IPD) was carried out in all Australian states and territories in 2005 with comparative data available since 2001. There were 1,680 cases of IPD notified to the National Notifiable Diseases Surveillance System in Australia in 2005; a notification rate of 8.3 cases per 100,000 population. The rates varied between states and territories and by geographical region with the highest rates in the Northern Territory, the jurisdiction with the largest proportion of Indigenous people. Invasive pneumococcal disease was reported most frequently in those aged 85 years or over (41 cases per 100,000 population) and in 1-year-old children (36.5 cases per 100,000 population). Enhanced data provided additional information on 1,015 (60%) of all notified cases. The overall rate of IPD in Indigenous Australians was 8.6 times the rate in non-Indigenous Australians. There were 126 deaths attributed to IPD resulting in an overall case fatality rate of 7.5%. While the rate of IPD in the Indigenous under 2-year-old population decreased from 219 cases per 100,000 population since targeted introduction of the 7-valent conjugate pneumococcal vaccine (7vPCV) in 2001, the rate in 2005 (94 cases per 100,000 population) was significantly greater than in non-Indigenous children (20.4 cases per 100,000 population). Rates of disease in all children aged less than 2 years, caused by serotypes in the 7vPCV decreased by 75% between 2004 and 2005 as a result of the introduction of a universal childhood 7vPCV immunisation program. Significant decreases in IPD caused by 7vPCV serotypes also occurred in the 2–14 years and 65 years or over age groups. There is no evidence of replacement disease with non-vaccine serotypes. Serotypes were identified in 90% of all notified cases, with 61% of disease caused by serotypes in the 7vPCV and 88% caused by serotypes in the 23-valent polysaccharide pneumococcal vaccine (23vPPV). Reduced penicillin susceptibility remains low and reduced susceptibility to 3rd generation cephalosporins is rare. Commun Dis Intell 2007;31:92–106.
Downloads
References
Pneumococcal disease in Australia. Med J Aust 2000;173:S17–S64.
Roche PW, Krause VL, Bartlett M, Coleman D, Cook H, Davis C, et al. Invasive pneumococcal disease in Australia, 2004. Commun Dis Intell 2006;30:80–92.
Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003;348:1737–1746.
Lexau CA, Lynfield R, Danila R, Pilishvili T, Facklam RR, Farley M, et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 2005;294:2043–2051.
Centers for Disease Control and Prevention. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease – United States, 1998–2003. MMWR Morb Mortal Wkly Rep 2005;54:893–897.
Poehling KA, Talbot TR, Griffen MR, Craig AS, Whitney CG, Zell E, et al. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA 2006;295:1668–1674.
Greene CM, Kyaw MH, Ray SM, Schaffner W, Lynfield R, Barrett NL, et al. Preventability of invasive pneumococcal disease and assessment of current polysaccharide vaccine recommendations for adults: United States, 2001–2003. Clin Infect Dis 2006;43:141–150.
Australian Institute of Health and Welfare. 2004 Adult vaccination survey: summary results. 2005. Available from: http://www.aihw.gov.au/publications/index.cfm/title/10109 Accessed on 2 February 2007.
Menzies R, McIntyre P. Vaccine preventable diseases and vaccination policy for Indigenous populations. Epidemiol Rev 2006.
Hanna J, Humphreys J, Murphy D. Invasive pneumococcal disease in Indigenous people in north Queensland, 1999–2004. Med J Aust 2006;184:118–121.
Roche P, Krause V. Invasive pneumococcal disease in Australia, 2001. Commun Dis Intell 2002;26:505–519.
Millar EV, O'Brien KL, Watt JP, Brondson MA, Dallas J, Whitney CG, et al. Effect of community-wide conjugate pneumococcal vaccine use in infancy on nasopharyngeal carriage through 3 years of age: a cross-sectional study in a high-risk population. Clin Infect Dis 2006;43:8–15.
Hammitt LL, Bruden DL, Butler JC, Baggett HC, Hurlbert DA, Reasonover A, et al. Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease. J Infect Dis 2006;193:1487–1494.
Byington CL, Samore MH, Stoddard GJ, Barlow S, Daly J, Korgenski K, et al. Temporal trends of invasive disease due to Streptococcus pneumoniae among children in the Intermountain West: emergence of non-vaccine serogroups. CID 2005;41:21–29.
Whitney CG, Pilishvili T, Schaffner W, Craig AS, Lynfield R, Nyquist AC, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-controol study. Lancet 2006;368:1495–1502.
Steenhof AP, Shah SS, Ratner AJ, Patil SM, McGowan KL. Emergence of vaccine-related pneumococcal serotypes as a cause of bacteremia. CID 2006;42:907–914.
Gottlieb T, Collignon P, Robson J, Pearson JMH, Bell J. Streptococcus pneumoniae survey: 2005 antimicrobial susceptibility report. Canberra: Australian Group for Antimicrobial Resistance; 2006.
Kyaw MH, Lynfield R, Schaffner W, Craig AS, Hadler J, Reingold A, et al. Effect of the introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 2006;354:1455–1463.
Watson M, Roche P, Bayley K, Bell JM, Collignon P, Gilbert GL, et al. Laboratory surveillance of invasive pneumococcal disease in Australia, 2003 – predicting the future impact of the universal childhood conjugate vaccine program. Commun Dis Intell 2004;28:455–464.
Downloads
Published
How to Cite
License
Copyright (c) 2007 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
